Unsupported Price Increase Assessment

Protocol

April 11, 2023

Institute for Clinical and Economic Review
## Table of Contents

1. Background ........................................................................................................................................ 1
2. List of Drugs to Review....................................................................................................................... 2
3. Manufacturer Input ........................................................................................................................... 6
4. ICER Review........................................................................................................................................ 7
5. Designation of Drug Price Increases as “Unsupported” ................................................................. 9
6. Manufacturer Review Prior to Public Release ............................................................................... 10
7. UPI Report Public Release ............................................................................................................. 11

References ........................................................................................................................................... 13
1. Background

The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. For example, both California and Vermont now have laws tracking substantial drug price increases, requiring drug manufacturers to submit information that might justify increases above a certain threshold.\textsuperscript{1-3}

In 2019, with funding from Arnold Ventures, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, to identify major drugs with substantial price increases without adequate evidence to justify the increases. To guide our work, we receive input from a multi-stakeholder advisory group comprised of representatives from patient advocacy organizations, drugmakers, and insurers.

Please see the figure below for an overview of the timeframe for the 2023 UPI report to be released later this year.

<table>
<thead>
<tr>
<th>Timeline for Report Year 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 15 Manufacturer Notification and Input Period</td>
</tr>
<tr>
<td>Manufacturer Input Phase I</td>
</tr>
<tr>
<td>Preliminary Individual Assessments to Manufacturers</td>
</tr>
<tr>
<td>Manufacturer Input Phase II</td>
</tr>
<tr>
<td>Final Report Posted</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data Review Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main List Price Increase Period</td>
</tr>
<tr>
<td>Main List Evidence Review Period</td>
</tr>
<tr>
<td>Medicare Part B Price Increase Period</td>
</tr>
</tbody>
</table>

As detailed below, ICER proposes to generate a report of up to 13 drugs that have experienced substantial price increases over a one-year time period. ICER will review changes in the evidence base for these drugs, and report on whether potential evidentiary support for price increases was found.

It is important to note that ICER does not currently have the capacity to perform full economic analyses on the large number of therapies that will be subject to analysis as part of this report process, nor would the time needed to develop full ICER reports (at least eight months) provide information in a useful timeframe for the public and policymakers. Therefore, UPI reports are not intended to determine whether a price increase for a drug is fully justified by new clinical evidence or meets an ICER health-benefit based price benchmark. Instead, we will focus the analysis on whether substantial new evidence exists that \textit{could} justify its price increase. By identifying whether there is, or is not, new evidence for drugs with substantial price increases, we hope to provide the public and policymakers with information they can use to advance the public debate on drug price increases.
2. List of Drugs to Review

As described in greater detail below, the process for ICER’s review will start by identifying the top 250 drugs by net sales revenue in the United States (US), administered in any setting, across all insurers. From this list, the next step will be to identify drugs that have had list (wholesale acquisition cost or WAC) price increases that exceed the medical Consumer Price Index (CPI) over a one-year period by more than 2%. Drugs with list price increases that meet this threshold will also have their one-year net price increase determined. We will then rank drugs by the expected change in budget impact due to that change in net price over one year and then select the top 10 drugs whose net price increase would have generated the largest increase in budget impact at the national level. Based in part on public input, we will supplement that list with up to three additional drugs with price increases over the same timeframe that have not led to placement within the top 10 drugs by budget impact. Further details on the process are provided below. The date periods are described in the table above in Section 1.

2.1. Creating the List of Drugs with “Substantial” Price Increases

2.1.1. ICER will obtain a list of the 250 drugs with the largest net sales revenue in the US in the year prior to the Report Year. This information will come from SSR Health, LLC, an independent investment research firm, and may leverage other data sources for companies that are not publicly traded.

2.1.2. ICER will determine average WAC price changes for these drugs over the one-year Main List Price Increase Period described in the table above. The intent is to look at individual pricing decisions. As such, a rise in price across multiple manufacturers of a generic medication that in combination had a large change in budget impact would not be included in the review.

2.1.3. ICER will determine which of these drugs have had a WAC price increase over the one-year Main List Price Increase Period that exceeded the rate of medical CPI by more than 2%. This will be calculated as the difference between the average medical CPI at the beginning and end of the Main List Price Increase Period of interest using unadjusted rates (average CPI for starting year vs. average CPI for ending year); because of reporting, the exact dates of WAC price changes and CPI changes may be slightly different. The medical CPI is one of eight major components of the CPI recorded and reported by the US Bureau of Labor Statistics (BLS). Medical CPI comprises medical care services (professional services, hospital and related services, and health insurance) and medical care commodities (medical drugs, equipment, and supplies). Drugs whose WAC price increases have not exceeded the rate of medical CPI by more than 2% will be removed from further evaluation (that is, if medical CPI were 3%, WAC increase would need to be greater than 5%). Our intent in choosing the overall medical CPI and not its subcomponents is to reflect inflation in drug prices relative to inflation in the overall price of medical care.

2.1.4. Among those drugs with a WAC price increase more than 2% above medical CPI, ICER will determine net price changes over the one-year Main List Price Increase Period. WAC and net price
change per unit over the one-year period will be adjusted for percentage change in price across
different dosing strengths for any drug, if applicable, considering the relative sales volume of the
various dosing strengths. Net price information will be obtained from SSR Health.

2.1.5. ICER will rank those drugs whose net price increases have had the largest impact on US
spending over the prior year. To create this ranking, ICER will use calculations by SSR Health that
dollarize the impact of net price changes year-on-year to give a representative rank-ordering of the size
of the impact by product during the Main List Price Increase Period, driven by both size of the product
(in terms of total net sales) and size of the net price impact.

2.1.6. ICER will contact the manufacturers of the top 15 drugs on the list to inform them that their
drugs will potentially be reviewed as part of the UPI process. Manufacturers will have three weeks
to contact ICER with any concerns about ICER’s estimates of average price changes or budget
impact. To dispute one of these estimates (other than concerns about a mathematical calculation
error), manufacturers will need to provide ICER with corrected figures that ICER may publish as part
of the UPI report. This information must include either:

- The effect of net price changes on change in revenue over the period in question

  Or

- The average net prices and total volumes of sales for each of the two years in question.

2.1.7. After resolution of any concerns about estimates, ICER will remove from the list any therapy
with an increase in budget impact due to increase in net price that is smaller than $25 million.

2.1.8. The top 10 drugs remaining on the list will constitute the first part of the final list of drugs for
which the evidence review will be undertaken. Drugs below position 10 will not be included except
as described in Sections 2.1.8 and 2.2 below.

2.1.9. If after notification to manufacturers of the selections for the top 15 drugs (manufacturers
are only notified of their own drugs on the list), a manufacturer provides ICER with information as
described in Section 2.1.6 that would have led to the drug’s removal from the top 10 list had it been
provided by the deadline, the drug will only be removed from evaluation if the effect of net price
change on revenue over the period in question is not positive.

2.2. Additional Drugs to be Reviewed

Therapies with large increases in price can present substantial problems of affordability to
individual patients whether or not net price increases as well and even if the total budget impact of
the price increase on the medical system is not large. This is particularly likely to occur with
therapies that already have a high list price where patients are likely to be required to pay a
percentage of the cost (coinsurance), and where manufacturer pricing assistance is not permitted
or available.
So, as to focus on therapies likely to present such burdens to individual patients, the 2023 UPI report will examine up to three additional therapies that are heavily covered within the Medicare Part B program.

2.2.1. ICER will use publicly available US government data to create a list of drugs covered by Medicare Part B that had average annual total spending (including Medicare payment, deductible, and coinsurance) of at least $50,000 per patient during the last year of the Medicare Part B Price Increase Period. Methodology of the Medicare Part B spending by drug dataset is found [here](#). In brief, “Analyses of Medicare Part B drugs are possible for all Part B fee-for-service Medicare beneficiaries, but exclude any beneficiaries in the Medicare Advantage program (which represents over 35% of the Medicare population). The Medicare Part B Spending by Drug dataset focuses on average spending per dosage unit and change in average spending per dosage unit over time. Drug spending metrics for Medicare Part B drugs are based on total spending, which is derived from summing the three revenue center payment fields on the claim referring to Medicare payment, deductible, and coinsurance. This represents the full value of the product, including the Medicare payment and beneficiary liability.”

2.2.2. ICER will remove from the list any therapies that had an increase in average spending per dosage unit during the Medicare Part B Price Increase Period of less than medical CPI + 2%.

2.2.3. ICER will rank the therapies in the dataset by the following algorithm: average annual total spending per patient in the first year of the Medicare Part B Price Increase Period multiplied by the percentage change in average spending per dosage unit (from first to last year of the Medicare Part B Price Increase Period) multiplied by the total number of patients who used the drug in the last year of the Medicare Part B Price Increase Period. This algorithm emphasizes changes in spending per dosage unit while not allowing for the estimate to be impacted by changes in patients who use the drug from one year to the next or by changes in level of use from one year to the next.

2.2.4. ICER may choose to eliminate drugs that were already reviewed as Additional Drugs in the prior two years so as to avoid duplicating reviews of these drugs.

2.2.5. ICER will contact the manufacturers of the top three drugs on this list that were not previously reviewed on the main list for that same time period (the main list from the prior year UPI report) to ensure that the manufacturer has not previously or currently contested the relevant government dataset results for their drug. If the results are already in the process of being contested, ICER will move sequentially down the list to find three uncontested drugs.

2.2.6. These top three drugs will be reviewed as Additional Drugs in the current UPI report. If a drug would have been included but was already reviewed on the prior year main list or was removed for being on a recent Additional Drug list, this will be highlighted separately in the report.

2.2.7. ICER will report on price changes and impact of these price changes on individual patients as well as the Medicare dataset population for the Medicare Part B Price Increase Period.
2.3. Final Lists

The lists from Sections 2.1 and 2.2 will be reviewed as distinct lists in the report. ICER will not publicly announce these lists while the review is taking place, as we heard concerns from manufacturers that being on such a list would be stigmatizing when a determination has not yet been made as to whether the price increase is unsupported.
3. Manufacturer Input

ICER acknowledges that manufacturers may have information on their drugs and/or on competitor drugs that they believe justifies a substantial price increase. ICER will contact manufacturers of the 10-13 drugs on the lists and invite submission of this information within four weeks of notification. Importantly, any information provided by manufacturers will be included as part of the final report and will therefore be transparent to the public and policymakers.

Specifically, ICER will ask each manufacturer for the following information:

- New evidence or analyses published or presented over the two-year Evidence Review Periods that demonstrate improved clinical or economic outcomes compared with what was previously believed
- Older evidence that led to a new approved indication for the drug within the two-year Evidence Review Periods
- New evidence or analyses published or presented over the two-year Evidence Review Periods relating to comparator therapies that the manufacturer believes indicate clinical advantages of their drug
- Other potential justifications for a price increase, including new information within the two-year Evidence Review Periods, related to:
  - A large increase in costs of production
  - Large price savings attributable to the drug in other parts of the health care system
  - All other reasons deemed relevant by the manufacturers.

As noted below, at the time of outreach, ICER will also seek manufacturer input on which indications result in approximately 10% or more of the overall utilization of that drug. If manufacturers report that an indication is currently below 10% of overall use but is rapidly increasing and evidence related to that indication is one justification for a price increase, ICER will consider reviewing evidence related to this indication.
4. ICER Review

4.1. Overview of Review Process

For each drug, ICER will determine all existing or new (within prior two years) indication(s) that are responsible for approximately 10% or more of the drug’s utilization. To determine which indications meet this threshold, ICER will seek manufacturer input and also elicit input from clinical experts and payers. If manufacturers report that use for an indication is rapidly increasing and is the justification for a price increase, ICER will consider reviewing evidence related to this indication even if current use is below 10% of overall utilization. Additionally, if a manufacturer notes that a combination of indications that exceed 10% of overall utilization each individually have new evidence that could provide support for a price increase, ICER will take this into consideration in deciding which indications to review.

4.1.1. For all included indications, ICER will determine a baseline of known safety and clinical effectiveness as reflected in the evidence contained in the Food and Drug Administration (FDA) labeling information.

4.1.2. ICER will then perform independent systematic reviews looking for new information from randomized controlled trials (RCTs) on benefits and harms within these indications published or presented during our Evidence Review Period. However, if manufacturers have submitted evidence, ICER may choose not to perform a systematic review. ICER will not independently look for information other than from RCTs but will assess RCT and non-RCT information published or presented during our Evidence Review Periods that is submitted by manufacturers. Submitted studies may include RCTs, meta-analyses, economic models, and observational data. Studies reporting patient-reported outcomes and other real-world data will be highly relevant. For information on low frequency harms, evidence from large uncontrolled studies will also be relevant.

Note that the Medicare Part B Evidence Review Period is one year earlier for the three Additional Drugs.

4.1.3. For therapies that are being evaluated in sequential report years, ICER will only review evidence that became available since the prior review. If evidence supported a finding of a price increase with new evidence in the prior review, it will not be considered even if it falls within the two-year timeframe.

4.1.4. ICER will assign separate ratings to the quality of new evidence and to the magnitude of new net benefit demonstrated by the new evidence or analyses. The quality of evidence will be rated using three-level GRADE as low, moderate, or high. GRADE is largely congruent with ICER’s evidence ratings and allows certainty in estimates of effect to be separated from the magnitude of benefit for this purpose.

For the rating of new net benefit, ICER will use its usual approach to take a comprehensive view of both benefits and harms, including anything that appears to be evidence of new patient-important benefits or harms. ICER will also consider evidence of economic benefits or harms.
For evidence that is rated as being of moderate or high quality, ICER will rate the new net benefit as none, small, or substantial using the usual ICER Evidence Rating Matrix.

ICER’s drug value assessment reports determine additional net health benefit by comparing the new therapy to placebo or to alternative treatment options. However, for the UPI reports, the comparison will be between what was previously generally believed about a therapy (whether its clinical or economic effects) and what new evidence or analyses have demonstrated. A new analysis (such as a meta-analysis) simply confirming what was previously believed or a new trial confirming the prior estimates of a drug’s benefits will not substantially change what is believed about a therapy’s effects (clinical or economic).

In the event that a drug was approved under the FDA Accelerated Approval pathway, ICER will consider new evidence that narrows uncertainty or confirms that a surrogate outcome predicted a patient-important outcome even if this evidence does not substantially alter prior beliefs.

Manufacturers and others can refer to ICER’s responses to comments in Appendix K of the 2020 UPI report for examples of reasons why submitted evidence was viewed as not leading to ratings of “with new evidence.”
5. Designation of Drug Price Increases as “Unsupported”

Drugs found to have moderate/high quality new evidence or analyses of substantial improvement in benefit compared with what was previously believed will be categorized as having a “price increase with new evidence.” Drugs that have no new evidence or analyses, or evidence or analyses that do not meet these criteria, will be categorized as having price increases “unsupported by new evidence.” As described earlier, all manufacturer information submitted to justify the price increase will be provided as a component of this report, but any rationales that do not stem from new studies or new analyses will not be evaluated by ICER as a determinant in whether the drug is categorized as having its price increase unsupported by evidence.

In the unusual circumstance that multiple indications of a drug that, in aggregate, exceed 10% of utilization despite no one of the indications exceeding 10% utilization, and where every one of the indications individually has moderate or high quality evidence of a substantial new benefit compared with what was previously believed, ICER will consider this to be a price increase with new evidence.
6. Manufacturer Review Prior to Public Release

The manufacturer of each drug reviewed will be contacted and sent a preliminary analysis of the evidence and ultimate categorization of whether the price increase for their drug is unsupported by new evidence. Manufacturers will have four weeks to submit comments about their drug(s). These comments must be emailed as a Microsoft Word attachment to publiccomments@icer.org, must use Times New Roman 12-point font size, and must not be longer than five pages (excluding references and appendices). ICER will have previously asked manufacturers for information on indications of the drug that comprise 10% or more of the drug’s use and will not accept information on new indications for review at this stage.
7. UPI Report Public Release

7.1 Public Release Process

7.1.1. With manufacturer input and further reflection, the report will be revised as necessary to produce a version for public release. The UPI report will be the first public presentation of the results of the analysis that began with the identification of the top 250 drugs by sales in the US.

7.1.2. For the 10 drugs that comprise the main list, the report will include current net sales revenue, the change in list price (average list price for Main List Price Increase Period), and the change in net price (average net price for Main List Price Increase Period). It will also include a description for each drug of how the figures led sequentially from 1) largest net sales revenue; 2) changes in WAC exceeding medical CPI by more than 2%; 3) largest changes in net price; 4) largest increases in net sales revenue. This will show how the drug list was culled from the original 250 drugs to the 10 reviewed drugs.

For the three additional drugs, the Report will include the change in average annual payment per patient (average annual payment during Medicare Part B Price Increase Period) and the average number of patients receiving the therapy under Medicare Part B. The report will also include a description for each drug of how the figures led sequentially from 1) average annual payments ≥$50,000 (including Medicare and patient liability), 2) largest year-over-year increases in average annual payments multiplied by average number of patients receiving the therapy. The report will present the reviews/categorizations of the 13 drugs. As noted earlier, manufacturer comments will be published along with ICER’s responses to those comments as an appendix.
8. Key Changes in Process for 2023 UPI Report

Changes for the 2023 UPI report include:

1) In the unusual circumstance that multiple indications of a drug that, in aggregate, exceed 10% of utilization despite no one of the indications exceeding 10% utilization, and where every one of the indications individually has moderate or high quality evidence of a substantial new benefit compared with what was previously believed, ICER will consider this to be a price increase with new evidence.

2) For the Additional List (Medicare Part B) review, ICER may choose to eliminate drugs that were previously on the Additional List in the past two years.

ICER continues to expect that situations may arise that were not fully anticipated in this protocol and recognizes that it may need to alter aspects of the review to maintain transparency and fairness to all parties. ICER again commits to flexibility within this review and to transparency about any needed changes.
References


